Governance
Investors
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dodekin
    • Dekavil
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • About us
    • Profile
    • Management
    • Board
    • Scientific Advisory Board
  • Our Science
    • Strategy
    • Enabling Technologies
    • Product Classes
  • Pipeline
    • Pipeline
    • NidlegyTM
    • Fibromun
    • Darleukin
    • Dekavil
    • Dodekin
    • Onco IX
    • OncoFAP Radio Conjugates
    • Tripokin
  • Press Releases & Events
  • Work with us
    • Careers
    • Partnering
  • Investors
    • Investor Relations
    • Shareholding
    • IPO
    • Press Releases
    • Financial Statements
    • Financial Calendar
    • Internal Dealing
    • Buyback
    • Analyst Coverage
    • Webinars
    • IR Contacts
  • Governance
    • Board of Directors
    • Board of Statutory Auditors
    • Documents & Procedures
    • Shareholders’ Meetings
    • Codice etico e Modello 231
    • Sustainability (ESG)

Philogen Receives Orphan Drug Designation for the Treatment of Melanoma

Jul 18, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE DAROMUN

Philogen Announces Exercise of Options Within the License Agreement With AbbVie in the Field of Immuno-Inflammation

Feb 28, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE, FEBRUARY 28TH 2018

Philogen and the Scripps Research Institute announce research collaboration in the field of DNA-Encoded Chemistry.

Jan 8, 2018 | 2018, Press Releases, Scientific

PRESS RELEASE – PHILOCHEM SCRIPPS

Recent Posts

  • Sun Pharma and Philogen enter into an Exclusive Distribution, License, and Supply Agreement for Commercializing specialty product, NIDLEGY™ in Europe, Australia and New Zealand (Price Sensitive)
  • Sun Pharma e Philogen stipulano un Accordo di commercializzazione, Licenza e Fornitura in esclusiva per il prodotto innovativo Nidlegy™ in Europa, Australia e Nuova Zelanda (Price Sensitive)
  • 29 maggio 2023 – Aggiornamento sul programma di acquisto di azioni proprie
  • Philogen Publishes New Data on a Fibromun-based treatment combination in Science Translational Medicine in collaboration with the University Hospital Zürich
  • Deposito del Verbale dell’Assemblea degli Azionisti

Recent Comments

    Privacy Policy / Cookie Policy

      Contacts

    • Follow
    • Follow

    Philogen S.p.A. ©  Piazza La Lizza, 7 | 53100 Siena (SI) – ITALY | Nr. REA: SI-98772 | P.IVA e CF 00893990523 | Cap. Soc. € 5.731.226,64 i.v. | PEC: AFC@pec.philogengroup.it